Skip to main content
CELC logo

CELC · Celcuity Inc.

Track CELC — free
$56.91 +1.31 (+2.36%)
Market Cap
$2.73B
Shares
49.13M
Volume · Nov 19 74.43K Avg daily vol (3M) 1.23M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$55.60 Open$57.62 Day$55.48–58.12 52W close$55.60–144.98 Avg vol 30d1.5M Short int10.3M · 21.0% of shares · 5.9d Short vol38% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Dec 11, 2026 Est · unconfirmed · in 3 wks

Latest documents

2026
Nov 5
Earnings call
ReftraPIC launch advances as losses deepen

Celcuity Inc. launched ReftraPIC on September 30th; 78% of its top 36 accounts ordered, and 91% of U.S. commercial and Medicare lives are covered. No third-quarter product revenue was recognized; cash, cash equivalents, and short-term investments reached $642.7 million.

5 source passages
Earlier today, Cellcuity, Inc. released financial results where the quarter ended September 30, 2026. Since ReftraPIC became commercially available on September 30th, 78% of the top 36 strategic accounts have ordered ReftraPIC. 91% of U.S. commercial and Medicare lives are in health care plans that cover ReftorPIC. Because no product was received at the treatment location, Until after September 30th, 2026, we did not recognize any product revenue during the third quarter of 2026. Cash, cash equivalents, and short-term investments were $642.7 million at the end of the third quarter, compared to $441.5 million as of December 31, 2025. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
REVTORPYK launches after FDA approval

Celcuity launched REVTORPYK after FDA approval for adults with HR+/HER2- ABC without a PIK3CA mutation, but recognized no product revenue through September 30, 2026; its nine-month net loss was $205.0 million.

Net loss $73.34M Diluted EPS -$1.33
Read from the MD&A section
3 source passages
On July 14, 2026, the FDA approved our NDA for REVTORPYK in HR+/HER2- ABC, for use in adult patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Shipments of REVTORPYK commenced on September 30, 2026. We recognize revenue when control of REVTORPYK transfers to the healthcare providers or pharmacies, which generally occurs upon delivery of REVTORPYK based on contractual shipping terms. Because no product was received by the healthcare providers or pharmacies until after September 30, 2026, we did not recognize any product revenue during the three and nine months ended September 30, 2026. During the nine months ended September 30, 2026 and 2025, we reported a net loss of $205.0 million and $126.1 million, respectively. Open the document at this passage
Nov 5
Current report 8-K
REVTORPYK launches as net loss reaches $73.3 million

Celcuity Inc. launched REVTORPYK on September 30, 2026, with 91% of U.S. commercial and Medicare lives covered; third-quarter net loss was $73.3 million, and no product revenue was recognized.

Financial results
4 source passages
Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the third quarter ended September 30, 2026, and other recent business developments. 91% of U.S. commercial and Medicare lives are in health plans that cover REVTORPYK Net loss for the third quarter of 2026 was $73.3 million, or $1.33 per share, compared to a net loss of $43.8 million, or $0.92 per share, for the prior year period. Because no product was received by the healthcare providers or pharmacies until after September 30, 2026, we did not recognize any product revenue during the third quarter ended September 30, 2026. Open the document at this passage
Oct 2
Current report 8-K Events of Oct 1
Director or officer change, or executive pay, Regulation FD disclosure

Celcuity Inc. appointed David W. Gryska to its expanded nine-member Board effective October 1, 2026, and to its Audit and Compensation Committees, with a $70,000 annual cash retainer, $100,000 annual equity award, and 893 restricted stock units.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$256.01M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-7.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$642.70M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.9%
Year over year · more shares
Price change (1Y)
-39.3%
Trailing year
Short interest
21.0%
Latest settlement · 5.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. The REVTORPYK launch showed broad account uptake and payer coverage, while positive mutant-cohort data supported an sNDA and clinical results were reported in breast and prostate cancer. However, Celcuity recognized no product revenue in the quarter, its net loss and operating cash burn increased, operating expenses rose, a $50.0 million milestone was paid to Pfizer, and temporary J-code reimbursement friction remains for some accounts.

Bullish
  • + The REVTORPYK launch reached 78% of the top 36 strategic accounts, representing ~50% of the addressable patient population.
  • + REVTORPYK achieved broad payer coverage, with 91% of U.S. commercial and Medicare lives in covered health plans.
  • + In PIK3CA mutant patients without liver metastases, median PFS was 21.5 months for the gedatolisib triplet and 11.5 months for the doublet versus 9.1 months for alpelisib plus fulvestrant.
  • + Celcuity submitted an sNDA for the PIK3CA mutant indication and plans additional global regulatory submissions.
  • + In mCRPC patients previously exposed to abiraterone, median rPFS was 15.7 months and the six-month rPFS rate was 82.2%.
  • + Current cash, cash equivalents and investments are expected to finance operations through 2029.
Bearish
  • − Third-quarter net loss widened to $73.3 million, or $1.33 per share, from $43.8 million, or $0.92 per share.
  • − No product revenue was recognized during the third quarter because no product was delivered until after quarter-end.
  • − Total operating expenses increased to $77.3 million from $42.8 million, while R&D expenses increased to $37.5 million from $30.4 million.
  • − SG&A expenses increased by $27.4 million to $39.8 million, primarily because of commercialization staffing and infrastructure.
  • − Net cash used in operating activities increased to $66.2 million from $44.8 million, and Celcuity paid a $50.0 million milestone to Pfizer.
  • − The temporary J-code creates reimbursement friction for some accounts until it becomes active on April 1.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −43%
below
Price vs 50-day avg −21%
below
RSI (14) 32
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −10%
trailing
6-month return −58%
trailing
YTD return −44%
this year
Relative strength −55%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $70 › 200d $98 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +48 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
20.97% of shares out · ▲ +0.5% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
273 holders — near 3-yr high, broad support
Squeeze score 76
high risk · 0–100
Fundamentals
Weak
EPS growth −34%
Y/Y
Free cash flow $-153.5M
Balance sheet $28.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 64%
annualized · 1-yr
Max drawdown −62%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−43% Bearish
Price vs 50-day avg
−21% Bearish
RSI (14)
32 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $70 › 200d $98 — 200d above 50d
Institutional flow Distributing
-2% holders QoQ · +48 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
20.97% of shares out · ▲ +0.5% MoM · 5.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
273 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $56 Now $56 · 0% Range high $145
vs 200-day avg -43% vs 50-day avg -21%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Health care providers who attended REVTORPYK educational programs 1,100 as of November 5, 2026 —
Non-GAAP adjusted net loss non-GAAP -$172.35M Nine Months Ended September 30, 2026 —
Non-GAAP adjusted net loss per share non-GAAP $1.21 third quarter of 2026 —
Non-GAAP adjusted net loss per share - basic and diluted non-GAAP -$3.14 Nine Months Ended September 30, 2026 —
Sites directly engaged with Celcuity oncology sales specialists 3,400 as of November 5, 2026 —
Top 36 strategic accounts that have ordered REVTORPYK 78% as of November 5, 2026 —
U.S. commercial and Medicare lives in health plans that cover REVTORPYK 91% as of November 5, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CELC
Celcuity Inc.
this stock
$2.73B -44.3% — — 21.0%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
273
% held
117.8%
Net QoQ
+1.1M sh
Top holder
BAKER BROS. ADVISORS LP
Held Float
View
Held by Funds
Fund positions
264
View
Short & Settlement
Short Interest Rising
Shares short
10.3M
Days to cover
5.9d
Change
+50.9K sh
View
Short Volume
Short vol %
38%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
15.9K
Value
$1.1M
As of
Oct 5, 2026
View
Off-Exchange
Off-exchange %
55.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Tom Malinowski
Amount
$1.0K–$15.0K
Traded
May 26, 2021
View
Financials
Financials
Net income (FY)
$-177.0M
EPS diluted
$-3.79
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 18, 2026
This year
30
View
Proposed Sales
Value
$291.0M
Shares
2.8M
Filed
Jul 14, 2026
View
Exempt Offerings
Offering
$352.7M
Filed
Sep 23, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Celcuity Announces FDA Acceptance…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
CELC -13.6% -9.7% -58.2% -19.6% -44.3%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -9.7% -4.1% -54.7% -16.2% -51.3%
Key facts CIK 1603454 CUSIP 15102K100 13F (30d) 273 filings 259 filers Visit website Investor relations